Results 221 to 230 of about 240,995 (321)

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the real‐world effectiveness of semaglutide versus tirzepatide in reducing major adverse cardiovascular events (MACE) among patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes in an insured US population.
Lauren Wilson, Zhenxiang Zhao, Victoria Divino, Matthew Bassan, Bríain Ó. Hartaigh, Signe Stensen, Kerem Ozer   +6 more
wiley   +1 more source

Percutaneous Coronary Intervention [PDF]

JAMA, 2004
openaire   +1 more source

Predictors and prognosis of no-reflow during primary percutaneous coronary intervention

, 2018
Govindan Nair Rajesh, Narayanapillai Jayaprasad, Suresh Madhavan, V. Sudha Kumary, K Jayaprakash, Kamarudheenkunju Jameelabeevi Raihanathul Misiriya, Vaikathusseril Lembodaran Jayaprakash, Raju George   +7 more
openalex   +2 more sources

Incidence and clinical consequences of distal embolization on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction [PDF]

, 2008
M. L. Fokkema, Pieter J. Vlaar, Tone Svilaas, Mathijs Vogelzang, D. Amo, Gilles F.H. Diercks, Albert J.H. Suurmeijer, Felix Zijlstra   +7 more
openalex   +1 more source

Association between CMR‐derived hepatic T1‐time, tricuspid regurgitation and survival

European Journal of Clinical Investigation, EarlyView.
We investigated the association between tricuspid regurgitation (TR) severity and hepatic T1‐time in 1029 patients undergoing cardiac MRI and echocardiography. Hepatic T1‐time increased progressively with TR severity and remained independently associated after adjusting for NT‐proBNP and right ventricular function. Both TR and hepatic T1‐time predicted
Katharina Mascherbauer, Christina Kronberger, Manuel Gruber, Carolina Donà, Matthias Koschutnik, Varius Dannenberg, Michael Poledniczek, Laura Lunzer, Christian Nitsche, Franz Duca, Gregor Heitzinger, Kseniya Halavina, Dietrich Beitzke, Christian Loewe, Michael Trauner, Philipp Bartko, Julia Mascherbauer, Christian Hengstenberg, Andreas Kammerlander, Elisabeth Waldmann   +19 more
wiley   +1 more source

Clinical Outcomes and Sustainability of Using CYP2C19 Genotype–Guided Antiplatelet Therapy After Percutaneous Coronary Intervention [PDF]

, 2018
Craig R. Lee, Vindhya Sriramoju, Alexandra Cervantes, Lucius A. Howell, Nicholas Varunok, Shivanshu Madan, Kasey Hamrick, Melissa J. Polasek, John Andrew Lee, Megan M. Clarke, Jonathan D. Cicci, Karen E. Weck, George A. Stouffer   +12 more
openalex   +1 more source

Effectiveness of direct oral anticoagulants for all‐cause mortality and cardiovascular events in overweight and obese patients with atrial fibrillation: Insight from the nationwide START registry

European Journal of Clinical Investigation, EarlyView.
This study shows that overweight and obese patients with atrial fibrillation experience improved outcomes when treated with DOACs compared with VKAs. Specifically, DOAC use was associated with lower risks of all‐cause mortality and cardiovascular events.
Danilo Menichelli, Gianluca Gazzaniga, Emilia Antonucci, Gualtiero Palareti, Daniela Poli, Pasquale Pignatelli, Daniele Pastori, the START2 Register Investigators, Benilde Cosmi, Daniela Poli, Elena Lotti, Martina Berteotti, Walter Ageno, Giovanna Colombo, Salvatore Bradamante, Eugenio Bucherini, Monica Vastola, Paola Casasco, Antonio Chistolini, Alessandra Serrao, Luciano Crippa Ambulatorio Emostasi, Raimondo De Cristofaro, Erica De Candia, Valeria De Micheli, Marcello Di Nisio, Anna Falanga, Teresa Lerede, Elvira Grandone, Donatella Colaizzo, Antonio Insana, Nicola Lucio Liberato, Domenico Lione, Rosa Maria Lombardi, Giacomo Lucarelli, Giuseppe Malcangi, Catello Mangione, Giuliana Martini Centro Emostasi, Marco Marzolo, Giovanni Nante, Vincenzo Oriana, Paolo Pedico, Simona Pedrini, Vittorio Pengo, Antonietta Piana, Francesco Cibecchini, Simona Pezzella, Pasquale Pignatelli, Daniele Pastori, Vincenza Rossi, Lucia Ruocco, Paolo Chiarugi, Serena Rupoli, Domizio Serra, Carmine Spataro, Margherita Reduzzi, Sophie Testa, Oriana Paoletti, Vincenzo Toschi, Claudio Vasselli   +58 more
wiley   +1 more source

Impact of Left Ventricular End-Diastolic Pressure on Percutaneous Coronary Intervention Outcomes. [PDF]

J Soc Cardiovasc Angiogr Interv
Siano M, Jobanputra Y, Oliva A, Sartori S, Smith K, Kaur H, Sweeny J, Dangas GD, Mehran R, Kini AS, Sharma SK.   +10 more
europepmc   +1 more source

IL‐6 in the spotlight: From cardiovascular pathophysiology to therapy

European Journal of Clinical Investigation, EarlyView.
Interleukin‐6 (IL‐6) links inflammation to cardiovascular and multi‐organ dysfunction. This review integrates mechanistic, translational, and clinical evidence supporting IL‐6 as both a biomarker and therapeutic target in the continuum of cardiovascular and cardio‐renal disease.
Alberto Preda, Amedeo Tirandi, Giulio Leo, Davide Di Vece, Gemma Vilahur, Aldo Bonaventura, Elena Osto, Stefano Ministrini, Simon Kraler, Petra Kleinbogard, Giovanni Camici, Federico Carbone, Fabrizio Montecucco, Luca Liberale   +13 more
wiley   +1 more source

Teleoperated robotic surgical system for percutaneous coronary intervention. [PDF]

Comput Struct Biotechnol J
Hsu HF, Huang CC, Shen YT, Chu HW, Yang CC, Kao HL, Hsiao HM.   +6 more
europepmc   +1 more source